ProsTIC

The first @APCCC_Lugano 2015 did not mention PSMA PET once! CT plus bone scan were deemed sufficient to define metastatic disease (77% consensus for M0). +11 years: the #APCCC26 report on high-risk localised and biochemically recurrent disease is out in @EUplatinum, with 67 questions referencing PSMA PET or next-generation imaging. I pulled those votes into a single wheel to highlight there are many areas of disagreement amongst the experts and much work to do! Publication here: sciencedirect.com/science/ar… Congrats to the growing APCCC panelists led by @Silke_Gillessen @AOmlin

Pushing Terbium-161 PSMA Theranostics to 9.5 GBq - VIOLET Clinical Trial results at the #EANM26 @EANM_NucMed Terbium-161 emits beta radiation like lutetium-177, plus ultra-short range Auger and conversion electrons that may better target micrometastases. Our first-in-human VIOLET trial established safety up to 7.4 GBq (Lancet Oncology 2025). So we asked: can we go higher? 12 men with mCRPC, 9.5 GBq, up to 6 cycles: - Remarkably well tolerated: just 1 grade 3 toxicity (anaemia) - PSA50 response 75%, PSA90 response 33% - Median PSA-PFS and rPFS not reached The answer is yes - and we’re not stopping ... Cohort C, a dose-dense cohort with shorter intervals between early cycles, is now underway. Huge thanks to @PCF_Science Young Investigators @ButeauJames , @LouiseKostos and @AzadOncology , and to the whole @PeterMacCC @pros_tic team who made this investigator-initiated trial possible. Grateful to @Isotopia_Global and the for their support #TOP (Top Rated Oral Presentation)

LuCAB at #ESMO26 - Combination Lu-177 PSMA-617 + cabazitaxel in mCRPC, accepted in @TheLancetOncol Adding taxane chemotherapy to LuPSMA may overcome heterogeneous PSMA expression and act as a radiosensitiser. 35 pts, post-docetaxel + ARPI: 🧪 No DLTs: cabazitaxel 20 mg/m2 + 7.4 GBq LuPSMA ⚠️ G3 TRAEs 24%, no G4/5 📈 RP2D (n=26): PSA50 73%, rPFS 10.9 mo, OS 16.5 mo Impressive outcomes in an unfavourable cohort (29% M1c). Randomised trials needed: chemo + LuPSMA together or in sequence? 🙏 Led by @LouiseKostos & @AzadOncology with @ButeauJames , Grace Kong, @pj_physics, @DrBenTran, @MHaskali, @declangmurphy @PeterMacCC and @drlouiseemmett @StVincentsSyd Above all, thank you to the patients and families who took part. Funded by @PCFnews through @pros_tic , with PSMA-617 supplied by @Novartis plus additional support. @myESMO

Check-out the @urotoday coverage of @pros_tic #ProsTIC26 urotoday.com/conference-high… Thanks @zklaassen_md for travelling to Melbourne to cover the meeting live. @PCF_Science Coverage growing by the hour!

Want to learn more about THERANOSTICS? 360+ delegates. 25 countries. First class international and national Faculty. Only one week to go #ProsTIC26 There is still time to join us in Melbourne - register now at prostic26.org and book your flights! Features industry, nuclear medicine doctors, radiopharmaceutical scientists, medical physicists, nuclear medicine technologists, nurses, radiation oncology, urology, medical oncology, clinical trials staff + more. Don't miss it. ProsTIC24 highlights below - not only educational but a lot of fun.